See more : Subaru Co., Ltd. (9778.T) Income Statement Analysis – Financial Results
Complete financial analysis of Vertex, Inc. (VERX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vertex, Inc., a leading company in the Software – Application industry within the Technology sector.
You may be interested
- PT Tifico Fiber Indonesia Tbk (TFCO.JK) Income Statement Analysis – Financial Results
- Wise Ally International Holdings Limited (9918.HK) Income Statement Analysis – Financial Results
- Ercros, S.A. (ECR.MC) Income Statement Analysis – Financial Results
- Daou Technology Inc. (023590.KS) Income Statement Analysis – Financial Results
- JUPITER INDUSTRIES & LEASING L (JPTRLES.BO) Income Statement Analysis – Financial Results
Vertex, Inc. (VERX)
About Vertex, Inc.
Vertex, Inc. provides tax technology solutions for corporations in retail, communication, leasing, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also provides implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. Vertex, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 572.39M | 491.62M | 425.55M | 374.67M | 321.50M | 272.40M |
| Cost of Revenue | 223.81M | 193.13M | 161.89M | 165.39M | 110.38M | 95.70M |
| Gross Profit | 348.58M | 298.49M | 263.66M | 209.28M | 211.12M | 176.71M |
| Gross Profit Ratio | 60.90% | 60.72% | 61.96% | 55.86% | 65.67% | 64.87% |
| Research & Development | 58.21M | 41.88M | 44.02M | 54.34M | 30.56M | 23.76M |
| General & Administrative | 145.94M | 121.65M | 107.01M | 149.06M | 71.01M | 58.95M |
| Selling & Marketing | 140.24M | 125.34M | 99.01M | 99.42M | 68.13M | 56.90M |
| SG&A | 286.17M | 246.99M | 206.01M | 248.48M | 139.14M | 115.85M |
| Other Expenses | 21.70M | 17.71M | 16.57M | 11.22M | 9.57M | 7.25M |
| Operating Expenses | 366.09M | 306.57M | 266.60M | 314.04M | 179.27M | 146.85M |
| Cost & Expenses | 579.81M | 499.71M | 428.49M | 479.42M | 289.65M | 242.54M |
| Interest Income | 0.00 | 1.68M | 984.00K | 1.72M | 1.08M | 526.00K |
| Interest Expense | 4.16M | 2.05M | 984.00K | 3.11M | 2.04M | 1.59M |
| Depreciation & Amortization | 74.46M | 76.28M | 56.73M | 32.22M | 25.19M | 24.90M |
| EBITDA | 56.95M | 53.07M | 41.84M | -72.54M | 58.13M | 22.07M |
| EBITDA Ratio | 9.95% | 10.80% | 9.83% | -19.36% | 18.08% | 20.10% |
| Operating Income | -7.42M | -8.08M | -2.94M | -104.76M | 31.86M | -2.83M |
| Operating Income Ratio | -1.30% | -1.64% | -0.69% | -27.96% | 9.91% | -1.04% |
| Total Other Income/Expenses | -14.25M | -2.05M | -984.00K | -3.11M | -953.00K | -34.41M |
| Income Before Tax | -21.67M | -10.13M | -3.93M | -107.87M | 30.90M | -4.43M |
| Income Before Tax Ratio | -3.79% | -2.06% | -0.92% | -28.79% | 9.61% | -1.63% |
| Income Tax Expense | -8.58M | 2.17M | -2.45M | -28.93M | 7.83M | 1.68M |
| Net Income | -13.09M | -12.30M | -1.48M | -78.94M | 23.08M | -6.11M |
| Net Income Ratio | -2.29% | -2.50% | -0.35% | -21.07% | 7.18% | -2.24% |
| EPS | -0.09 | -0.08 | -0.01 | -0.54 | 0.21 | -29.08 |
| EPS Diluted | -0.09 | -0.08 | -0.01 | -0.54 | 0.21 | -29.08 |
| Weighted Avg Shares Out | 151.86M | 149.65M | 147.78M | 146.44M | 146.17M | 210.00K |
| Weighted Avg Shares Out (Dil) | 151.86M | 149.65M | 147.78M | 146.44M | 146.17M | 210.00K |
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
Vertex Pharmaceuticals is working on a therapy to treat diabetes. The latest data about that therapy's performance looks solid.
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Everyone's Talking About Vertex Pharmaceuticals. Is It Time to Buy?
Vertex Pharmaceuticals recently turned heads with clinical trial results for VX-880, an off-the-shelf cellular therapy for type 1 diabetes patients. Treatment with VX-880 helped patients produce insulin independently and reduced their reliance on daily injections.
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe...
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the annual European Hematology...
Vertex Acquires Artificial Intelligence Tax Capabilities from Ryan, LLC
KING OF PRUSSIA, Pa., June 12, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, announced today the acquisition of tax-specific AI capabilities from Ryan, LLC, an award-winning tax services and...
Vertex Shares Rising on Expanded Therapy Offerings
Global biotechnology company Vertex Pharmaceuticals Incorporated (VRTX) is a market-beating outlier stock.
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), also known in the European Union and in the U.K. as KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor, were presented at this year's European Cystic Fibrosis...
Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time
Biotech companies, like Vertex Pharmaceuticals, benefit from patents, driving consistent growth. Vertex excels in cystic fibrosis treatments and boasts a promising pipeline of new drugs. Vertex's innovation spans pain management and kidney health, with late-stage developments like Vanzacaftor showing significant...
3 Overlooked Tech Stocks Aiming for a 10X Surge
The Nasdaq hit a record high after Fed chairman Jerome Powell reassured investors with his comment. The central bank's next interest rate move is more likely not to be a hike, even though inflation has been higher than expected.
Source: https://incomestatements.info
Category: Stock Reports